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ABSTRACT
Background. A limited number of psychotherapy sessions in combination with medication is pref-
erable to pharmacotherapy only in the treatment of ambulatory patients with major depression.
Whether there is a relation between the number of sessions and the eﬃcacy of the treatment is
uncertain.
Method. Randomized clinical trial comparing two treatment conditions in outpatients with major
depression. All patients studied had a baseline score of at least 14 points on the 17-item Hamilton
Depression Rating Scale. The two conditions consist of 8-session or 16-session Short Psycho-
dynamic Supportive Psychotherapy, both in combination with pharmacotherapy. Eﬃcacy was as-
sessed using the 17-item HDRS, the CGI of Severity and of Improvement, the depression subscale
of the SCL-90 and the Quality of Life Depression Scale.
Results. The rate of change would seem to indicate that eight sessions are preferable for both
moderately and severely depressed patients, although the results converged again at the end. Fur-
thermore, in terms of satisfaction with the number of sessions and drop-out percentages during
treatment, no diﬀerences were found between the conditions.
Conclusion. In the light of the outcome analysis (faster remission after fewer sessions), a short
version of the psychotherapy treatment in a combined course of treatment seems to be justiﬁed.
INTRODUCTION
In the sixties, seventies and eighties longer
courses of psychotherapy appeared to be more
eﬀective for depression than shorter courses
(Luborsky et al. 1971; Smith et al. 1980;
Howard et al. 1986; Orlinsky et al. 1994). In the
eighties however, there were also studies which
arrived at diﬀerent conclusions (Shapiro &
Shapiro, 1982; Miller & Berman, 1983; Berman
et al. 1985; Robinson et al. 1990; Mynors-
Wallis et al. 1995; Scott et al. 1997). Frank &
Kupfer (1985) were among the ﬁrst to question
explicitly the prevailing consensus that ‘ longer’
also meant ‘better ’.
The nineties witnessed the emergence of a
trend towards brief courses of treatment with
detailed protocols. Studies of these forms of
treatment are easier in practical terms. Treat-
ment costs less and it may be more eﬃcient than
longer-term forms of psychotherapy. Several
studies showed that certain forms of psycho-
therapy [i.e. cognitive behaviour therapy (CBT)
or interpersonal psychotherapy (IPT)] could
achieve a satisfactory reduction in symptoms in
a short space of time (Hollon & Najavits, 1988;
Dobson, 1989; Thase et al. 1997; DeRubeis et al.
1999; Jarrett et al. 1999; Keller et al. 2000).
Little systematic research has been conducted
in recent decades into the ideal dosage of
psychotherapy. One of the few studies conduc-
ted in this area is the Second Sheﬃeld Psycho-
therapy Project of Shapiro et al. (SPP2; 1994).
This study assigned patients randomly to 8 or 16
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sessions of IPT or CBT. The study showed that,
when the entire study population was con-
sidered, there was no diﬀerence between the re-
sults obtained by 8 or 16 sessions. For patients
with severe depression, 16 sessions were more
eﬀective than 8 sessions. In mild depression the
best result was achieved with 8 sessions rather
than 16 sessions. This study has been criticized
for the fact that it was not corrected for phar-
macotherapy. Some patients were eﬀectively
given combined treatment, whereas others re-
ceived psychotherapy only.
Results from a substudy of the SPP2 project
(Barkham et al. 1996a) covering the ‘dose–
eﬀect ’ relationship indicate that patients with 8
sessions achieve a clinically relevant change be-
fore patients with 16 sessions. However, at the
end of the treatment, the outcomes of both
conditions were the same.
In a replica study of the SPP2 project, the
Collaborative Psychotherapy Project (CPP;
Barkham et al. 1996b), it was found that 16
sessions produced more beneﬁts than 8 sessions
in the study population as a whole. Given the
fact that more severely depressed patients par-
ticipated in this CPP study than in the SPP2
project, this ﬁnding would appear to concur
with the diﬀerential eﬀect found in the SPP2
project. A limitation of the CPP study was the
low number of trial subjects (n=36) – in con-
trast to the number in the SPP2 project
(n=117) – and the lack of correction for phar-
macotherapy.
The present study deals with this drawback
of the SPP2 and CPP studies. We studied the
eﬀect of short-term versus longer-term psycho-
therapy in a group of 90 patients who were given
pharmacotherapy alongside psychotherapy.
The authors are not aware of any similar study.
The patients [suﬀering from at least moderate
depression according to DSM-IV criteria (APA,
1994)] were allocated at random to 8 or 16
sessions of psychotherapy supplemented by
pharmacotherapy for a period of 6 months. We
studied the extent to which the patients in
both conditions recovered from the depressive
disorder. We also looked at levels of satisfac-
tion among the patients and therapists with a
number of psychotherapy sessions. Finally, we
analysed the levels of compliance for medi-
cation and psychotherapy and/or levels of drop
out for the study.
Our a priori hypothesis for this study was that
the 16-session condition would beneﬁt more in
terms of depression severity.
METHOD
Study group
The study sample consisted of all consecutive
patients newly registered (n=1467) during a
period of approximately 2 years at an outpatient
clinic of Mentrum Mental Health in the inner
city of Amsterdam. The diagnosis of major de-
pression was made by psychiatrists on the basis
of a semi-structured interview which covered
depression characteristics, severity and duration.
The inclusion criteria were: age between 18 and
60 years, DSM-IV (APA, 1994) deﬁned major
depression (with or without dysthymia), a 17-
itemHamiltonDepressionRating Scale (HDRS)
(Hamilton, 1967; de Jonghe et al. 1994) base-
line score of at least 14 points and written in-
formed consent. Important exclusion criteria
were, e.g. presentation of a psycho-organic dis-
order, drug abuse, a psychotic disorder and/or a
dissociative disorder ; patient considered to be
too unreliable to participate in a clinical trial
(e.g. ‘shopping’, which is a frequent change of
institution) ; a serious communicative problem
(e.g. language barrier) making participation in
the trial impossible; participation in the trial
being physically impossible (e.g. the patient will
soon leave the country) ; a contraindication for
one of the antidepressants prescribed by the
pharmacotherapy protocol is in force. Ad-
ditional exclusion criteria were of the usual kind
in drug research: the patient is considered ‘too
ill ’ by the psychiatrist (e.g. antidepressants must
be started immediately) and/or ‘ too suicidal ’
(e.g. hospitalization is unavoidable) to partici-
pate in a clinical trial. For the ﬂow of par-
ticipants see Fig. 1.
Procedure of randomization
The question of the relative 6-month eﬃcacy of
the two treatment methods was addressed in a
randomized parallel group design. The patients
were randomized using block-randomization.
Four blocks were formed, deﬁned by sex and
age. The patients were randomly allocated to
either the 8-session or 16-session psychotherapy
condition. The sessions lasted 45 min. The ﬁrst
8 sessions were weekly in both conditions.
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Psychotherapy in the 8-session condition then
stopped; in the 16-session condition, the last 8
sessions took place at intervals of 2 weeks. In
both conditions, the patients were treated for a
period of 6 months in accordance with a ﬁxed
antidepressant protocol.
Obviously, the patients and the treating phys-
icians were not blind. The three research
fellows who assessed the HDRS, however, were
not informed about the treatment condition and
were instructed to restrict themselves to the dis-
cussion of the HDRS items only. The trial was
preceded by a 2-week period in which the diag-
nosis was assessed using a semi-structured
interview (Huyser et al. 1996). During the same
period, the inclusion and exclusion criteria were
checked, and the baseline assessments were
made. This period was used, if necessary, as a
wash-out period (without placebo).
Pharmacotherapy
All patients in the two study groups were treated
for a period of 6 months in accordance with a
ﬁxed antidepressant protocol. The medication
contacts lasted for 15 min at intervals of 2 weeks
during the ﬁrst 2 months. Thereafter, contacts
weremonthly.When there was a change ofmedi-
cation, contacts were again scheduled every 2
weeks during the 2 months following the change.
The task of the treating pharmacotherapist
Assessed for eligibility (n = 463)
Meeting inclusion criteria
for depression (n = 168)
Meeting exclusion
criteria (n = 295)
HRDS baseline <14 (n = 65)
Randomized (n = 103)
Allocated to intervention 
8-session condition (n = 49)
Received allocated intervention
(n = 45)
Refused allocated intervention
(n = 4)
Allocated to intervention 16-session 
condition (n = 54)
Received allocated intervention
(n = 45)
Refused allocated intervention
(n = 9)
FIG. 1. Flow of participants through ﬁrst stages of randomized trial.
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was to provide adequate pharmacotherapy
(motivation and monitoring of response and
side-eﬀects), psycho-education and limited sup-
portive contact. This has been described in the
literature as ‘warm pharmacotherapy’ (Hollon
et al. 1991). The pharmacotherapy protocol con-
sisted of three successive stages. Decisions about
changes in medication were made on the basis of
the clinical response (CGI-I) (see later for expla-
nation) and the presence of side-eﬀects (intoler-
ance). Initially, patients were given ﬂuoxetine in
a ﬁxed dose of 20 mg/day. In cases of intoler-
ance or ineﬃcacy, patients were switched to
nortriptyline. The initial dose was 50 mg/day,
rising to 150 mg/day and higher depending on
the plasma concentration. If intolerance or in-
eﬃcacy was found again, patients were switched
to mirtazapine. The initial dose was 15 mg/day,
rising to a maximum of 45 mg/day. If improve-
ment was unsatisfactory after treatment with the
three antidepressants listed here, patients were
classiﬁed as therapy-resistant and given further
treatment outside the study protocol as con-
sidered appropriate by the psychiatrist.
Psychotherapy: short psychodynamic supportive
psychotherapy (SPSP)
In addition to the pharmacotherapy described
above, the psychotherapy was given by seven
fully trained psychotherapists (who were not the
psychiatrists providing medication). They all
had at least 5 years’ experience in practising
psychoanalytic supportive therapy. They met
weekly for a 1-hour discussion of their audio-
taped sessions in order to enhance their adher-
ence to the psychotherapy manual [a draft of
which is available (in Dutch) from the authors
upon written request]. One of the authors
(F.d.J.), who formulated the guidelines for
SPSP, participated in most of these meetings,
listened to several tapes of all psychotherapists,
and was especially attentive to adherence to the
manual. Psychotherapy started within 2 weeks
after the initiation of pharmacotherapy. The
psychotherapy provided was SPSP.
The supportive approach is not new in
psychoanalysis. It has been described, for ex-
ample, as supportive psychotherapy (Werman,
1984), psychoanalytic supportive psychotherapy
(de Jonghe et al. 1994) and psychodynamically
oriented supportive therapy (Rockland, 1989).
It is generally seen as a segment of a supportive-
exploratory continuum (Rockland, 1989). The
short, brief, or time-limited approach in psycho-
analysis is not new either. Typically, time-limited
dynamic psychotherapy (Strupp & Binder,
1984), or brief dynamic psychotherapy, or short
psychoanalytically oriented therapy, are situated
towards the exploratory end of the supportive-
exploratory continuum. The emphasis is on
interpreting the transference (Strupp & Binder,
1984). SPSP, by contrast, is a brief approach
situated towards the supportive end of that
continuum.
Measurement of outcome
Eﬃcacy assessment was based on data from
three sources : the patients, the treating psy-
chiatrists, and independent observers. The in-
dependent observers, three research fellows who
were not informed of the treatment condition,
collected their data using the 17-item HDRS in a
semi-structured interview (de Jonghe, 1994), at
weeks 4, 8, 12, 16 and 24. The reliability of their
assessments was established prior to their par-
ticipation in the study. During the study, in
order to avoid slippage, they discussed their
audiotaped assessments monthly with one of
this paper’s authors (F.d.J.). The treating psy-
chiatrists obtained their data using the Clinical
Global Impression of Severity (CGI-S) and of
Improvement (CGI-I) (Guy, 1976) at weeks 4, 8,
12, 16 and 24. The patients provided data using
two self-rating scales: the depression subscale
of the Ninety Symptom Checklist (SCL-90)
(Derogatis et al. 1973;Arrindell&Ettema, 1986),
and the Quality of Life Depression Scale
(QLDS) (Tuynman-Qua & de Jonghe, 1992), at
weeks 8, 16 and 24 (logistics precluded the col-
lection of information for every measurement
scale at all the eight measurement moments).
In the analyses of the eﬃcacy of the treat-
ments, success is deﬁned as HDRS remission
(HDRS end score of 7 points or less), as a CGI
success (CGI-S or CGI-I score of 1–2), and as
SCL or QLDS success (an eﬀect size of at least 1
S.D. from base rate on the SCL-90 depression
subscale or QLDS).
Satisfaction with the number of psychotherapy
sessions
Both patients and psychotherapists were
instructed to complete the Luborsky inven-
tory (Luborsky et al. 1985) after the ﬁnal
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psychotherapy session. The scale consists of
twelve items. Eleven items were scored on a
6-point scale (ranging from 1 to 6, respectively
dissatisﬁed and very satisﬁed). Examples of
items include: degree of insight of the patient,
degree of trust in the therapist, satisfaction of
the working alliance, degree to which the target
in therapy is achieved. One of the items is re-
lated to their assessment of the number of
psychotherapy sessions. For this item response
categories were: too few, enough and too much.
Drop out
In order to determine the drop-out rates, three
diﬀerent measures were used. Patients who
stopped taking medication or attending psycho-
therapy sessions were considered to be pharma-
cotherapy drop-outs or psychotherapy drop-outs
respectively. This does not necessarily mean that
these patients are study drop-outs. Patients be-
came study drop-outs if, forwhatever reason, they
no longer appeared for the assessments or ref-
used to continue participating in the study. Drop
out from the study may also have been a conse-
quence of a decision taken by the psychiatrist
(not by the psychotherapist) if exclusion criteria
had been overlooked initially (e.g. alcohol
abuse) or had emerged after the start of treat-
ment (e.g. the wish to become pregnant), or if it
was impossible or undesirable to continue with
treatment based on the protocol (e.g. deterio-
ration of clinical condition). Finally, all proto-
col violations resulted in study drop-out.
Statistical methods
For the analyses of the outcome, we used the
following statistical analysis techniques.
(1) At weeks 4, 8, 12, 16 and 24, the mean
scores [SCL-90 and QLDS (not at weeks 4 and
16), see ‘measurement of outcome’] of each as-
sessment were in the conditions separately
compared with the scores of the last assessment.
Besides that, the between-group comparisons of
the continuous measures were analysed with
ANCOVA. In this analysis, we compared the
conditions at each assessment in terms of the
mean scores for the HDRS, SCL-90, QLDS and
CGI-S, including the initial measures as covari-
ants. At the end we conducted analyses of the
continuous measures with MANOVA.
(2) At weeks 4, 8, 12, 16 and 24, the remission
and succession rates of the two treatment
conditions were compared using 2-sided Pear-
son x2 (level of signiﬁcance 0.05).
(3) For the HDRS remissions, we also used
survival analysis. The Kaplan–Meier survival
estimates were calculated for weeks 4, 8, 12, 16
and 24, and the curves obtained were compared
using the log-rank test to take into account both
the rate of remission and the time needed to
achieve remission.
For the analyses of the satisfaction percent-
ages and the drop-out rates for the two treat-
ment conditions, we used 2-sided Pearson x2
(level of signiﬁcance 0.05).
These data analysis methods for outcome and
drop-out rates were conducted on three samples
of patients. The ﬁrst was the per protocol (PP)
sample. This sample consisted of all patients
who started the treatment to which they were
allocated. In other words, the patients who ref-
used after allocation were not taken into con-
sideration. Here also, an initial measure was
required for each patient. Secondary results
were calculated in an intention-to-treat (ITT)
sample, which consists of all randomized
patients. In both these samples last observation
carried forward was applied. Secondary results
were also calculated in an observed cases (OC)
sample, which consisted of all patients who did
not drop out after the start of the treatment. In
this article, we only present the results of the
analyses with the PP sample, because these re-
sults were almost the same as those of the ITT
and OC samples.
A limitation of the study is the statistical
power. At the start of the study, the idea was
to achieve an average recovery rate of 50% of
the patients in the 16-session condition and an
average recovery of 30% in the 8-session con-
dition. Assuming power of approximately 75%,
the intention was to involve approximately 130
patients in the study (65 in each condition).
There were fewer intakes than planned and
eventually 102 patients were included in the
study. Statistical power, therefore, failed to live
up to our initial assumption.
RESULTS
Patients
A total of 103 patients were randomized (8
psychotherapy sessions, n=49; 16 psycho-
therapy sessions, n=54). Of the randomized
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patients, 13 patients (12.6%) refused the pro-
posed treatment; nine in the 8-session condition
and four in the 16-session condition. Those who
refused the proposed treatment did not diﬀer
signiﬁcantly in HDRS, CGI, SCL-90 or QLDS
base rates from those who accepted it. In both
treatment conditions, 45 subjects actually started
the treatment.
No selection bias for demographic back-
ground or psychiatric history was found in our
sample. The characteristics of the study groups
(based on the PP sample) are presented in
Table 1.
As can be seen in Table 1, two thirds of
the study group were women. More than half
of the subjects were unmarried and well
educated.
In 59% of the cases, the duration of the
present episode was less than 1 year and less
than 2 years in 83% of the cases. Most patients
(83%) had not been treated during the present
episode or taken any antidepressant medication
during the 3 months before participation in this
study (80%). The mean baseline scores in the
study population were 19.9 on the 17-item
HDRS, 3.5 on the CGI-S, 50.6 on the SCL-90
depression subscale and 15.4 on the QLDS.
No statistically signiﬁcant diﬀerences were
found between the two treatment groups in
terms of the baseline scores on the measurement
Table 1. Characteristics of the per protocol study sample
Condition
Total
(n=90) %
8 sessions
(n=45) %
16 sessions
(n=45) %
Sex Male 40.0 31.1 35.6
Female 60.0 68.9 64.4
Age (years) 19–29 28.9 35.6 32.2
30–39 28.9 28.9 28.9
40–49 26.7 22.2 24.4
50–59 15.6 13.3 14.4
Marital status Married 42.2 20.5 31.5
Divorced 11.1 20.5 15.7
Widowed 2.2 0.0 1.1
Never married 44.4 59.1 51.7
Educational level Low 17.8 18.2 18.0
Intermediate 44.4 36.4 40.4
High 37.8 45.5 41.6
Living situation Living with at least one person 66.7 56.8 61.8
Living alone 33.3 43.2 38.2
Job status Job 42.2 31.8 37.1
On sickness beneﬁt 28.9 36.4 32.6
Social security beneﬁt 17.8 6.8 12.4
Disabled 2.2 6.8 4.5
Student 4.4 6.8 5.6
Other 4.4 11.4 7.9
Duration of present episode <1 year 61.4 56.8 59.1
1–2 years 15.9 31.8 23.9
>2 years 22.7 11.4 17.0
Psychiatric treatment during present episode Not treated 88.6 77.3 83.0
Treated 11.4 22.7 17.0
Medication 3 months before study No medication 79.5 79.5 79.5
Medication 20.5 20.5 20.5
Depressed episodes within previous 5 years 0 75.0 65.1 70.1
1 or 2 22.7 30.2 26.4
o3 2.3 4.7 3.4
HDRS* Mean (S.D.) 19.4 (3.8) 20.3 (4.4) 19.9 (4.1)
Median 19.0 20.0 19.0
CGI-Severity* Mean (S.D.) 3.5 (0.7) 3.6 (0.6) 3.5 (0.7)
Median 3.0 4.0 4.0
SCL-90 Depression subscale* Mean (S.D.) 49.3 (8.7) 52.0 (10.1) 50.6 (9.5)
Median 49.0 53.0 50.5
QLDS* Mean (S.D.) 16.1 (6.4) 14.8 (7.0) 15.4 (6.7)
Median 15.0 17.0 15.0
* The numbers presented are not percentages but means and standard deviations.
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instruments. Randomization was, therefore,
successful.
Outcome
In Table 2, we present means and standard de-
viations of the four outcome measures in the PP
sample. In the fourth and eight columns of this
table we present the signiﬁcance scores of the
paired t tests. Each time we compared the scores
of that assessment with the scores of the last
assessment. In the last three columns we present
the results of the ANCOVAs of the four out-
come measures in the PP sample. We used base-
line pre-treatment measurement as the covariate
before comparing the means at week 24.
Obviously, the treatment of depression in
both therapy conditions was successful.With the
paired t tests we observed signiﬁcant changes
in all outcome measures in the ﬁrst 8 weeks.
After week 8, there were only signiﬁcant further
falls in the scores in the 16-session condition (up
to week 16).
With the ANCOVA we see few diﬀerences
between the conditions at the various measure-
ment points. The few diﬀerences there are, in-
dicate that remission levels are higher at around
week 8 of the 8-session condition compared to
the 16-session condition. After 6 months, there
are no more diﬀerences between the 8- and
16-session conditions. In case of a Bonferroni
adjustment of the p value, the minor diﬀerences
which there are in favour of the 8-session con-
dition are negligible.
When we used a MANOVA with repeated
measurements, there was a signiﬁcant main
eﬀect of the treatment factor on the HDRS
(F=44, 8; p=0.00), CGI-S (F=60, 1; p=0.00),
CGI-I (F=23, 18; p=0.00) and QLDS (F=
39, 75; p=0.00), but there was not a main eﬀect
for the condition and also not an interaction
Table 2. Outcome scores for ﬁve outcome measures (per protocol sample)
Treatment ANCOVA
8 sessions
Signiﬁcance
paired t test
16 sessions
Signiﬁcance
paired t test
Signiﬁcance level
Mean S.D. n Mean S.D. n F df p
HDRS
Pre-treatment 19.4 3.8 45 20.3 4.4 45 1.10 1 0.30
Week 4 16.0 6.5 45 0.00 16.9 5.7 45 0.00 0.15 1 0.70
Week 8 12.6 6.9 45 0.00 15.3 6.6 45 0.05 2.77 1 0.10
Week 12 12.1 7.2 45 N.S. 13.7 6.8 45 0.04 0.61 1 0.44
Week 16 11.3 7.6 45 N.S. 12.0 6.9 45 0.04 0.23 1 0.88
Week 24 11.1 6.8 45 N.S. 12.1 7.6 45 N.S. 0.12 1 0.73
CGI-Severity
Pre-treatment 4.5 0.7 42 4.6 0.6 44 0.40 1 0.53
Week 4 3.7 1.0 45 0.00 4.0 0.9 45 0.01 1.18 1 0.28
Week 8 3.1 1.1 45 0.00 3.4 1.1 45 0.01 2.08 1 0.15
Week 12 2.8 1.3 45 0.06 3.1 1.1 45 0.03 1.35 1 0.25
Week 16 2.7 1.3 45 N.S. 2.8 1.1 45 0.03 0.66 1 0.42
Week 24 2.6 1.2 45 N.S. 2.7 1.3 45 N.S. 0.02 1 0.89
CGI-Improvement
Week 4 3.1 0.9 43 0.01 3.2 0.8 43 0.01 0.02 1 0.89
Week 8 2.7 1.0 44 N.S. 2.9 0.9 44 0.08 0.91 1 0.34
Week 12 2.5 1.1 44 N.S. 2.6 0.8 44 0.03 0.16 1 0.69
Week 16 2.4 1.2 44 N.S. 2.4 0.8 44 0.03 0.09 1 0.77
Week 24 2.3 1.0 44 N.S. 2.3 0.9 44 N.S. 0.19 1 0.67
SCL-Depression
Pre-treatment 49.3 8.7 45 52.0 10.1 45 1.85 1 0.18
Week 8 35.6 13.4 45 0.00 43.1 12.9 45 0.00 5.30 1 0.02
Week 16 34.6 13.6 45 N.S. 38.1 13.5 45 0.00 0.40 1 0.53
Week 24 35.2 12.8 45 N.S. 36.4 14.2 45 N.S. 0.04 1 0.85
QLDS
Pre-treatment 16.1 6.4 44 14.8 7.0 43 0.75 1 0.39
Week 8 21.8 8.9 45 0.00 19.1 8.0 45 0.00 1.34 1 0.25
Week 16 22.9 8.8 45 N.S. 21.8 8.1 45 0.02 0.09 1 0.77
Week 24 22.6 8.6 45 N.S. 22.8 8.3 45 N.S. 0.28 1 0.60
Combined psycho-pharmacological treatment for depression 53
eﬀect between treatment and condition. Con-
cerning the SCL scores, as well as the main eﬀect
of treatment (F=69, 98; p=0.00) there is also a
trend to an interaction eﬀect between treatment
and condition (F=2, 59; p=0.06), but not a
main eﬀect for condition.
Remission and success rates for the outcome
measures are presented in Table 3.
Again, there are virtually no diﬀerences be-
tween the conditions. The few trends that
there are indicate higher remission levels in the
8-session condition around week 8. These diﬀer-
ences in success percentages between the treat-
ment groups gradually disappeared at 16 and
24 weeks.
In terms of HDRS remission, the Kaplan–
Meier survival curves for the two treatment
groups in all of the three samples generate much
the same information. Fig. 2 plots the pro-
portion of patients against the number of weeks
until remission for the PP sample.
The 8-session treatment condition curve is
below that of the 16-session condition, meaning
that remission is reached earlier. The two curves
coincide after 24 weeks.
The mean time to achieve remission – deﬁned
as an HDRS score below 8 – is 16 weeks in
the 8-session condition and 18 weeks in the 16-
session condition. With the Kaplan–Meier sur-
vival analysis, we ﬁnd no signiﬁcant diﬀerence in
time to remission between the two treatment
groups at 24 weeks. During the ﬁrst 8 weeks,
however, there is a signiﬁcant diﬀerence in re-
mission rates (log rank=3.90; df=2; p=0.048).
At 8 weeks, 31% of the 8-session patients had
already reached remission, while remission had
Table 3. Success percentages and remission rates for ﬁve outcome measures (per protocol sample)
Treatment
Pearson x2 (2-sided)
signiﬁcance level8 sessions 16 sessions
n % n % x2 df p
HDRS remission
Week 4 7 15.6 3 6.7 1.80 1 0.18
Week 8 14 31.1 8 17.8 2.17 1 0.14
Week 12 13 28.9 11 24.4 0.23 1 0.63
Week 16 18 40.0 13 28.9 1.23 1 0.27
Week 24 15 33.3 13 28.9 0.21 1 0.65
HDRS reduction>50%
Week 4 8 17.8 5 11.1 0.81 1 0.37
Week 8 19 42.2 12 26.7 2.41 1 0.12
Week 12 17 37.8 16 35.6 0.05 1 0.83
Week 16 21 46.7 21 46.7 0.00 1 1.00
Week 24 19 42.2 19 42.2 0.00 1 1.00
CGI-Severity success
Week 4 4 8.9 2 4.4 0.71 1 0.40
Week 8 12 26.7 8 17.8 1.03 1 0.31
Week 12 19 42.2 12 26.7 2.41 1 0.12
Week 16 21 46.7 15 33.3 1.67 1 0.20
Week 24 22 48.9 21 46.7 0.05 1 0.83
CGI-Improvement success
Week 4 8 17.8 6 13.3 0.34 1 0.56
Week 8 20 44.4 16 35.6 0.74 1 0.39
Week 12 24 53.3 18 40.0 1.61 1 0.21
Week 16 27 60.0 26 57.8 0.05 1 0.83
Week 24 31 68.9 24 53.3 2.29 1 0.13
SCL-Depression success
Week 8 25 55.6 25 55.6 0.00 1 1.00
Week 16 29 64.4 30 66.7 0.05 1 0.82
Week 24 30 66.7 27 60.0 0.43 1 0.51
QLDS success
Week 8 18 40.9 14 32.6 0.65 1 0.42
Week 16 21 47.7 21 48.8 0.01 1 0.92
Week 24 20 45.5 26 60.5 1.97 1 0.16
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only been achieved in 18% of the 16-session
patients. The same analysis was made for both
SCL-90 and QLDS. There was also no signiﬁ-
cant diﬀerence for time to remission between
the two treatment groups at 24 weeks (SCL-90:
log rank=1.27; df=2; p=0.261 and QLDS: log
rank=0.19; df=2; p=0.665), in the PP sample.
With regard to the distribution of anti-
depressants taken, no signiﬁcant diﬀerence was
found between the conditions at measurement
times. The same applies to the mean dose per
antidepressant (according to the protocol).
Logistical regression analysis was conducted
to determine whether there was a link between
severity of depression at the start of the treat-
ment and remission. Here, HDRS remission was
the dependent variable and condition, sex, age,
severity of depression, marital status, edu-
cational level, and number of depressed episodes
were the independent variables. This analysis
showed that severity of depression at the start of
the treatment, as well as the other independent
variables, was not linked to remission during
treatment.
Satisfaction with the number of psychotherapy
sessions
Comparisons were made for the two conditions
between the total scores for the patient version
of the Luborsky and the scores for the therapist
version. None of the versions indicated a sig-
niﬁcant diﬀerence between the conditions. We
used a Pearson x2 (2-sided) test to determine
whether there were any diﬀerences between the
opinions of the patients and the therapists (on
the Luborsky item) about the right number of
psychotherapy sessions. Well over half (73%
in the 8-session condition and 58% in the 16-
session condition) of the therapists consider the
number of sessions to be adequate, with only
half of the patients being of the same opinion
(54% and 50% respectively). There is no
signiﬁcant diﬀerence between the conditions
(p=0.13; x2=4.1; df=2). Approximately 43%
of patients thought there were not enough
therapy sessions. Again, this applies equally to
both conditions (p=0.23; x2=2.9; df=1). Only
in the 16-session condition did 10% of both
therapists and patients say there were ‘ too
many sessions’. The others thought there were
‘enough’ sessions.
Therapy compliance
As we are looking at the eﬀect of a combined
therapy, reasons for drop out can be either dis-
continuation of pharmacotherapy or psycho-
therapy, or a violation of the study protocol. No
explicit discontinuations of psychotherapy were
registered. Based on the PP sample, we found no
diﬀerences in drop-out percentages between the
study conditions. In both conditions approxi-
mately 88% of the patients were still on medi-
cation 8 weeks after the start of the treatment.
After 6 months, this percentage was, in both
conditions, still approximately 76%. The dose
of medication or the switching to other medi-
cation (according to the pharmacotherapy pro-
tocol) did not diﬀer signiﬁcantly between the
conditions and could not have aﬀected the drop-
out rate.
DISCUSSION
Eight or 16 psychotherapy sessions in addition
to 8 sessions of pharmacotherapy over a period
of 6 months would appear to be equally eﬀec-
tive in terms of dealing with symptoms. That is
true for both moderately and severely depressed
patients. The minor advantage of 16 compared
to 8 sessions for severely depressed patients,
which was found in previous studies (Shapiro
et al. 1994; Barkham et al. 1996a) was, there-
fore, not conﬁrmed by our study. Remission was
faster in our study in the 8-session condition.
1·0
0·9
0·8
0·7
0·6
0·5
0·4
0·3
0·2
0·1
0·0
0 4 8 12 16 20 24
Time to remission (weeks)
Pr
op
or
tio
n 
no
t r
em
itt
ed
FIG. 2. The survival curves or the HDRS remission in the per
protocol sample. Treatment : —, 16 sessions ; - - - -, 8 sessions.
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What are the possible explanations for our
ﬁndings? With respect to faster remission in the
8-session psychotherapy condition, Reynolds
et al. (1996) also found a trend of faster re-
mission in the 8-session compared to the 16-
session condition. Eckert (1993) suggests that
there is an acceleration of therapeutic change
when a limit is imposed on the number of ses-
sions given to a client. He believes that it is,
therefore, possible to achieve the same result
with fewer sessions. If there is less time avail-
able, the therapeutic process can adapt and,
in general, the work is done more eﬃciently
(Howard et al. 1986). It is conceivable that
patients in the 8-session condition adopt a more
active attitude because they only have 8 sessions
in which to bring about an improvement. This
pressure may be less intense in the 16-session
condition.
After 6 months, the results of 8 or 16
psychotherapy sessions (accompanied by phar-
macotherapy) converged again. The 8-session
condition shows a relatively rapid decrease on
most of the outcome measures. Much of the
improvement occurred during the ﬁrst 8 weeks,
which runs parallel with the psychotherapy
sessions. A more gradual picture is seen in the
16-session condition, in which the outcome
scores at the end of treatment reach the same
values as in the 8-session condition. In terms of
dealing with symptoms, then, a longer course of
psychotherapy in a combined treatment context
does not lead to better results than brief
psychotherapy.
We found eﬀect sizes that corresponded to the
studies of Shapiro et al. (1994) and Barkham
et al. (1996b). They report eﬀect sizes of 1.77
and 1.60 respectively. In our study, we found an
eﬀect size of 2.18 for the 8-session condition and
of 1.86 for the 16-session condition. In a meta-
analysis, Thase et al. (1997) found recovery rates
of 43% in more severely depressed patients and
48% in patients with less severe symptoms.
These results are in accordance with our re-
mission rate of 42.2% in both conditions. Com-
pared to Keller et al. (2000), our results are not
impressive. The eﬀect size they found in their
study was 3.69. This is much higher than re-
ported in other studies. An explanation for
this result could be the relatively large number
of psychotherapy sessions in a short amount
of time.
An assessment of the level of satisfaction
among patients and therapists with the number
of psychotherapy sessions indicates that there
are no diﬀerences between the two conditions.
However, there are diﬀerences between ther-
apists and patients. Well over half (73% in the
8- session condition and 58% in the 16-session
condition) of the therapists consider the number
of sessions to be adequate, with only half of
patients being of the same opinion (54% and
50% respectively). The average percentage of
patients that thought that there were ‘too few’
sessions, was 43%. Despite improvements in
depression, a sizable percentage of the patients,
and to a lesser degree the therapists, there-
fore considered the number of psychotherapy
sessions to be inadequate.
When the number of drop-outs is taken into
consideration, there is once again no diﬀerence
between the conditions. Although neither the
distribution nor the mean dose of the anti-
depressants taken played a role in the outcome
scores, the main reason for drop-out was as-
sociated with pharmacotherapy. In this study,
none of the patients dropped out because of the
psychotherapy. It has been claimed that the ad-
dition of psychotherapy actually improves com-
pliance (Paykel, 1995; de Jonghe et al. 2001). It
would appear to be the case that 8 sessions of
psychotherapy generate the same level of medi-
cation compliance as 16 sessions of psycho-
therapy.
Several limitations of the study should be
mentioned. First, there is the selection bias in
the study population. The four inclusion criteria
and the nine exclusion criteria meant that a
speciﬁc group of depressed patients partici-
pated in this study. The selection criteria took
suitability for pharmacotherapeutic research
into account and not suitability for psycho-
therapeutic treatment, such as ego strength,
introspective ability, psychological aptitude or
verbal skills. Second, is the use of the CGI
scores in the outcome data. Because the treating
psychiatrist used this instrument to monitor the
clinical progress, it is not a totally independent
measure. This is overcome by using the HDRS
and the SCL-90 (both assessed by an indepen-
dent research fellow). Third, the study was
limited in terms of statistical power, although
the data does not give the impression that a
larger number of patients would have tilted the
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ﬁndings towards either condition. Furthermore,
the lack of a control group obstructs the
assessment of the eﬀectiveness of the two study
conditions.
It can be concluded that the rate of change
would seem to be in favour of the condition with
8 sessions, and that the results of both con-
ditions at the end converged again. In terms of
satisfaction about the number of sessions and
drop-out percentages during treatment, no dif-
ferences were found between the conditions.
Based on these results, one would appear to be
justiﬁed in concluding provisionally that a short
version of psychotherapy in a combined course
of treatment should be the treatment of choice.
However, this position would appear to be
premature. It is possible that the longer course
of psychotherapy, in the short term, will result
in improved functioning levels in the areas of
coping and social functioning. In the longer
term, this could result in the improvements be-
ing maintained and in the postponement of any
possible relapse. We hope to clarify these issues
in later publications.
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